Adam Craig Insider Profile
4 Followers
Adam Craig, EC, Director at X4 Pharmaceuticals, holds 328.65K shares in X4 Pharmaceuticals (Ticker: XFOR), holds 0.00 shares in CTI BioPharma (Ticker: CTIC), holds 23.45K shares in Viracta Therapeutics (Ticker: VIRX). Most recently, Adam Craig Sold ― shares of X4 Pharmaceuticals on Aug 13, 2026 for an estimated value of $210.62K.
Profitable Transactions
3 out of 3 Profitable Transactions
Average Return
+112.10%
Average return per transaction
Time Frame
Compare to
Insider Roles
EC, Director
Roles that Adam Craig holds in companies
Most Profitable Insider Trade
Stock:
CTI BioPharma
(CTIC)
(CTIC)
Rating:Informative Buy
Date:Dec 02, 2021 - Dec 02, 2022
Return:+315.90%
The most profitable trade made by Adam Craig
Adam Craig's Trading History
X4 Pharmaceuticals
Aug 13, 2026
EC, Director
Informative Sell
210.62K
$1.33M
Viracta Therapeutics
Mar 02, 2015
―
Uninformative Buy
―
$234.52
CTI BioPharma
Jun 26, 2023
―
Uninformative Sell
286.38K
$0.00
List of latest transactions for each holding click on a transaction to see Adam Craig's performance on stock
You May Also Like
Adam Craig insider profile FAQ
What is the percentage of profitable transactions made by Adam Craig?
The percentage of profitable transactions made by Adam Craig is 100%.
What is the average return per transaction made by Adam Craig?
The average return per transaction made by Adam Craig is 112.10%.
What stocks does Adam Craig hold?
Adam Craig holds: XFOR, VIRX, CTIC stocks.
What was Adam Craig’s latest transaction?
Adam Craig latest transaction was an Informative Sell of $210.62K.
What was Adam Craig's most profitable transaction?
Adam Craig’s most profitable transaction was an Informative Buy of CTIC stock on December 2, 2021. The return on the trade was 315.90%.
What is Adam Craig's role in X4 Pharmaceuticals?
Adam Craig's role in X4 Pharmaceuticals is EC, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.